使用自发报告系统数据库对免疫调节药物相关不良事件的药监测研究
Satoshi Nakao1,2, Mika Maezawa1, Moe Yamashita1
1Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
International journal of immunopathology and pharmacology
|April 10, 2025
概括
这项研究使用真实世界的数据比较了日本和美国的免疫调节药物 (IMiD) 相关的不良事件概况. 调查结果显示,IMID安全概况在各个国家之间存在差异,这突显了对患者安全的专注监测的必要性.
科学领域:
- 药物监督 药物监督 药物监督
- 现实世界的证据.
- 药物安全 药物安全
背景情况:
- 免疫调节药物 (IMiD) 用于癌症和炎症.
- 目前的风险管理侧重于胎儿影响,忽视患者特有的不良事件.
- 没有先前的研究在国际上比较IMiD相关不良事件 (ImrAE) 档案.
研究的目的:
- 评估和比较国家特定的ImrAE报告资料.
- 分析来自日本和美国的真实世界数据.
- 为了确定IMID安全性的潜在差异.
主要方法:
- 利用了日本药物不良事件报告 (JADER) 和FDA不良事件报告系统 (FAERS) 数据库.
- 定义的不良事件使用医学监管活动词典首选术语.
- 调查并比较了日本和美国报告的ImrAEs的数量.
主要成果:
- 骨髓抑制,肺炎和外围神经病变是两国常见的ImrAEs.
- 在日本和美国之间观察到ImrAE概况的显著差异.
- 报告的thalidomide,lenalidomide和pomalidomide的不良事件在每个国家都有不同的趋势.
结论:
- 对现实世界营销后数据的比较分析对于理解IMID的安全性至关重要.
- 每个国家特定的安全概况需要定制的监测策略.
- 焦点应该超越胎儿安全,包括患者经历的IMiDs的不良事件.
更多相关视频
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
500
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.6K
相关概念视频
Pharmacovigilance
753
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
753
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Allergic Drug Reactions
797
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
797
Analysis of Population Pharmacokinetic Data
202
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
202
Clinical Trials: Overview
2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
108
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
108
